Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Rating)’s share price fell 5.9% during mid-day trading on Thursday after SVB Securities downgraded the stock from an outperform rating to a market perform rating. SVB Securities now has a $42.00 price target on the stock. Halozyme Therapeutics traded as low as $37.41 and last traded at $37.68. 421,423 shares were traded during trading, a decline of 67% from the average session volume of 1,267,307 shares. The stock had previously closed at $40.05.
HALO has been the topic of a number of other reports. Morgan Stanley dropped their price target on shares of Halozyme Therapeutics from $65.00 to $64.00 and set an “overweight” rating on the stock in a research note on Monday, March 6th. JPMorgan Chase & Co. decreased their price target on Halozyme Therapeutics from $54.00 to $52.00 and set an “overweight” rating on the stock in a research note on Thursday, February 23rd. Wells Fargo & Company dropped their price objective on Halozyme Therapeutics from $65.00 to $55.00 and set an “overweight” rating for the company in a research note on Thursday. Benchmark lifted their price objective on Halozyme Therapeutics from $55.00 to $68.00 and gave the stock a “buy” rating in a report on Thursday, December 8th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $66.00 price objective (up from $62.00) on shares of Halozyme Therapeutics in a report on Wednesday, February 22nd. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $56.13.
Insider Buying and Selling
In related news, CEO Helen Torley sold 10,000 shares of the stock in a transaction that occurred on Tuesday, March 7th. The shares were sold at an average price of $45.47, for a total transaction of $454,700.00. Following the completion of the sale, the chief executive officer now owns 623,666 shares of the company’s stock, valued at approximately $28,358,093.02. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, CFO Nicole Labrosse sold 2,525 shares of the stock in a transaction that occurred on Thursday, February 16th. The shares were sold at an average price of $49.26, for a total transaction of $124,381.50. Following the completion of the sale, the chief financial officer now owns 9,066 shares of the company’s stock, valued at approximately $446,591.16. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Helen Torley sold 10,000 shares of the stock in a transaction that occurred on Tuesday, March 7th. The stock was sold at an average price of $45.47, for a total transaction of $454,700.00. Following the sale, the chief executive officer now directly owns 623,666 shares of the company’s stock, valued at approximately $28,358,093.02. The disclosure for this sale can be found here. In the last quarter, insiders sold 93,586 shares of company stock valued at $4,550,046. 2.30% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Halozyme Therapeutics
Halozyme Therapeutics Stock Performance
The stock has a market cap of $4.88 billion, a PE ratio of 24.88, a PEG ratio of 0.56 and a beta of 1.26. The company has a debt-to-equity ratio of 8.79, a quick ratio of 4.88 and a current ratio of 5.65. The stock has a fifty day simple moving average of $49.12 and a two-hundred day simple moving average of $48.73.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
- Get a free copy of the StockNews.com research report on Halozyme Therapeutics (HALO)
- Don’t Miss Out: $2 Trillion Could be Headed to the Banking Sector
- A Weakening Economy Suggests Caution Before Buying Five Below
- Williams-Sonoma: Time To Buy At Rock-Bottom Prices
- Why DraftKings Could Keep Outperforming in 2023
- Charles Schwab And The Safest 30% You Can Make This Year
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.